# Monte Rosa Therapeutics, Inc. (GLUE)

> Source: Nexqual · https://nexqual.com/GLUE · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Monte Rosa Therapeutics, Inc. (GLUE), nexqual.com/GLUE" · informational, not investment advice.

**Price:** USD 11.11 (-0.98% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 11.22 · day 11–11.38 · 52w 9.5–25.77 · market cap $948M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $28.7M, net income -$161M (-560.9% margin), free cash flow -$32.1M (SEC filings).
- Insider open-market sales, last ~7 months: 20 Form 4 filings, $2.9M; 6 not under a Rule 10b5-1 plan ($876K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (10 analysts), mean target USD 26.88 (range 19–37).
- Total return with dividends: 1Y +7.0% vs S&P 500 +14.9%; 5Y -51.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.2, revenue estimate $33.9M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $75.6M | $124M | $28.7M |
| Operating income | -$72.9M | -$112M | -$143M | -$81.1M | -$54.2M | -$182M |
| Net income | -$74.0M | -$109M | -$135M | -$72.7M | -$38.6M | -$161M |
| EPS (diluted) | -$2.96 | — | — | — | — | — |
| Free cash flow | -$69.1M | -$105M | -$62.8M | $38.0M | -$27.5M | -$32.1M |
| Operating margin | — | — | — | -107.3% | -43.8% | -633.0% |
| Net margin | — | — | — | -96.1% | -31.2% | -560.9% |
| Revenue growth | — | — | — | — | +63.5% | — |
| Cash + short-term investments | $346M | $54.9M | $128M | $224M | $377M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 33.0x · P/B 1.9x · FCF yield -3.38% · Earnings yield -17.00% · Dividend yield (paid, TTM) 0.00%

## Insider sales (SEC Form 4, open-market, last ~7 months)
14 of 20 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | Principal Accounting Officer | 13 | $0K | 0.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-16 | Warmuth Markus | President & CEO | 9,500 | $220K | 1.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-15 | Champoux Jennifer | Chief Operating Officer | 4,351 | $102K | 6.5% | Yes (adopted February 19, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-07-06 | Townson Sharon | Chief Scientific Officer | 6,000 | $140K | 8.1% | Yes (adopted February 27, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-30 | Janku Filip | Chief Medical Officer | 5,407 | $132K | 8.2% | Yes (adopted March 4, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-29 | Janku Filip | Chief Medical Officer | 6,000 | $138K | 9.1% | Yes (adopted March 4, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-29 | Manning Anthony M. | Director | 10,000 | $231K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23…2026-06-24 | Janku Filip | Chief Medical Officer | 41,845 | $882K | 41.1% | Yes (adopted March 4, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23 | Champoux Jennifer | Chief Operating Officer | 2,175 | $44K | 3.4% | Yes (adopted February 19, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23 | Townson Sharon | Chief Scientific Officer | 3,000 | $60K | 4.2% | Yes (adopted February 27, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-17 | Champoux Jennifer | Chief Operating Officer | 2,176 | $41K | 3.4% | Yes (adopted February 19, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-17 | Townson Sharon | Chief Scientific Officer | 3,000 | $57K | 4.2% | Yes (adopted February 27, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Warmuth Markus | President & CEO | 5,466 | $106K | 0.9% | Yes (adopted May 14, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Townson Sharon | Chief Scientific Officer | 6,000 | $119K | 8.1% | Yes (adopted February 27, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-27 | Champoux Jennifer | Chief Operating Officer | 2,175 | $44K | 3.4% | Yes (adopted February 19, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-22 | Champoux Jennifer | Chief Operating Officer | 2,176 | $41K | 3.4% | Yes (adopted February 19, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-21 | Manning Anthony M. | Director | 10,000 | $180K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Warmuth Markus | President & CEO | 5,467 | $103K | 0.9% | Yes (adopted May 14, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-14 | Warmuth Markus | President & CEO | 8,000 | $141K | 1.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-04-09 | Nickson Philip | Chief Business & Legal Officer | 5,845 | $103K | 9.6% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 10 analysts; mean target USD 26.88 (low 19, high 37).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-10-01 | HC Wainwright & Co. | Initiated | Buy | $25 |
| 2026-09-09 | Wedbush | Reiterated | Outperform | $27 |
| 2026-08-25 | Guggenheim | Reiterated | Buy | $28 |
| 2026-08-07 | JP Morgan | Target lowered | Overweight | $31 → $27 |
| 2026-08-07 | Guggenheim | Target lowered | Buy | $35 → $28 |
| 2026-08-07 | Wells Fargo | Target lowered | Overweight | $29 → $27 |
| 2026-08-03 | Wedbush | Target lowered | Outperform | $37 → $27 |
| 2026-06-30 | Guggenheim | Target raised | Buy | $30 → $35 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +7.0% | -51.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +7.1% | -13.4% |
| Volatility (annualized) | 79.3% | 93.7% |
| Max drawdown | -61.5% (Jan 2026→Oct 2026) | -89.2% (Nov 2021→Oct 2023) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/GLUE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-06)

- "Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026, were $626.0 million, compared to cash, cash equivalents, restricted cash, and marketable securities of $671.2 million as of March 31, 2026."
- "Monte Rosa expects that its cash, cash equivalents, restricted cash, and marketable securities will support operations into 2029."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.20 | $-0.38 | -47.0% | $33.9M | 9 |
| Next quarter (ends 2026-12-31) | $-0.36 | $-0.41 | -12.4% | $21.7M | 9 |
| Current fiscal year (ends 2026-12-31) | $-1.42 | $-1.59 | -11.0% | $68.3M | 9 |
| Next fiscal year (ends 2027-12-31) | $-1.85 | $-1.81 | +1.8% | $64.6M | 9 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±17.6%; last 8 reports averaged ±4.5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 72.3% | ±17.6% |
| 2026-12-18 | 56 | 108.4% | ±33.3% |
| 2027-01-15 | 84 | 134.9% | ±49.1% |
| 2027-04-16 | 175 | 94.5% | ±50.0% |